doi: 10.3109/10428194.2012.656103.
Epub 2012 Feb 13.
Waldenström macroglobulinemia: a Surveillance, Epidemiology, and End Results database review from 1988 to 2005
- PMID: 22239669
- DOI: 10.3109/10428194.2012.656103
Item in Clipboard
Waldenström macroglobulinemia: a Surveillance, Epidemiology, and End Results database review from 1988 to 2005
Leuk Lymphoma.
2012 Aug.
No abstract available
Similar articles
-
Survival trends in Waldenström macroglobulinemia: an analysis of the Surveillance, Epidemiology and End Results database.Blood. 2014 Jun 19;123(25):3999-4000. doi: 10.1182/blood-2014-05-574871. Blood. 2014. PMID: 24948623 No abstract available.
-
Survival of patients with lymphoplasmacytic lymphoma and solitary plasmacytoma in Germany and the United States of America in the early 21st century.Haematologica. 2017 Jun;102(6):e229-e232. doi: 10.3324/haematol.2016.157768. Epub 2017 Mar 9. Haematologica. 2017. PMID: 28280077 Free PMC article. No abstract available.
-
Prevalence and survival of smouldering Waldenström macroglobulinaemia in the United States.Br J Haematol. 2019 Mar;184(6):1014-1017. doi: 10.1111/bjh.15201. Epub 2018 Mar 13. Br J Haematol. 2019. PMID: 29532912 No abstract available.
-
Bing-Neel syndrome, a rare complication of Waldenström macroglobulinemia: analysis of 44 cases and review of the literature. A study on behalf of the French Innovative Leukemia Organization (FILO).Haematologica. 2015 Dec;100(12):1587-94. doi: 10.3324/haematol.2015.133744. Epub 2015 Sep 18. Haematologica. 2015. PMID: 26385211 Free PMC article. Review.
-
Survival in monoclonal gammopathy of undetermined significance and Waldenström macroglobulinemia.Clin Lymphoma Myeloma Leuk. 2013 Apr;13(2):187-90. doi: 10.1016/j.clml.2013.02.010. Epub 2013 Mar 13. Clin Lymphoma Myeloma Leuk. 2013. PMID: 23490991 Review.
Cited by
-
Coinhibition of the deubiquitinating enzymes, USP14 and UCHL5, with VLX1570 is lethal to ibrutinib- or bortezomib-resistant Waldenstrom macroglobulinemia tumor cells.Blood Cancer J. 2016 Nov 4;6(11):e492. doi: 10.1038/bcj.2016.93. Blood Cancer J. 2016. PMID: 27813535 Free PMC article.
-
Treatment paradigm in Waldenström macroglobulinemia: frontline therapy and beyond.Ther Adv Hematol. 2022 Apr 29;13:20406207221093962. doi: 10.1177/20406207221093962. eCollection 2022. Ther Adv Hematol. 2022. PMID: 35510210 Free PMC article. Review.
-
Revealing the Role of the Arg and Lys in Shifting Paradigm from BTK Selective Inhibition to the BTK/HCK Dual Inhibition - Delving into the Inhibitory Activity of KIN-8194 against BTK, and HCK in the Treatment of Mutated BTKCys481 Waldenström Macroglobulinemia: A Computational Approach.Anticancer Agents Med Chem. 2024;24(11):813-825. doi: 10.2174/1871520623666230208102609. Anticancer Agents Med Chem. 2024. PMID: 36752293
-
Management of lytic bone disease in lymphoplasmacytic lymphoma: A case report and review of the literature.Clin Case Rep. 2021 Dec 7;9(12):e05181. doi: 10.1002/ccr3.5181. eCollection 2021 Dec. Clin Case Rep. 2021. PMID: 34934497 Free PMC article.
-
New developments in the management of Waldenström macroglobulinemia.Cancer Manag Res. 2017 Mar 10;9:73-83. doi: 10.2147/CMAR.S94059. eCollection 2017. Cancer Manag Res. 2017. PMID: 28331368 Free PMC article. Review.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
